MX2019004492A - Metodos para tratar trastornos del higado o trastornos lipidicos con un agonista de thr-beta. - Google Patents

Metodos para tratar trastornos del higado o trastornos lipidicos con un agonista de thr-beta.

Info

Publication number
MX2019004492A
MX2019004492A MX2019004492A MX2019004492A MX2019004492A MX 2019004492 A MX2019004492 A MX 2019004492A MX 2019004492 A MX2019004492 A MX 2019004492A MX 2019004492 A MX2019004492 A MX 2019004492A MX 2019004492 A MX2019004492 A MX 2019004492A
Authority
MX
Mexico
Prior art keywords
disorders
thr
methods
treating liver
beta agonist
Prior art date
Application number
MX2019004492A
Other languages
English (en)
Inventor
Taub Rebecca
Original Assignee
Madrigal Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Madrigal Pharmaceuticals Inc filed Critical Madrigal Pharmaceuticals Inc
Publication of MX2019004492A publication Critical patent/MX2019004492A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención proporciona un método para tratar un trastorno hepático o trastorno lipldico en un sujeto en necesidad del mismo con 2-(3,5-dicloro-4-((5-isopropil-6-oxo-1,6-dihidropiri dazin-3- il)oxi)fenil)-3,5-dioxo-2,3,4,5-tetrahidro-1,2A-triazina- 6-carbonitrilo. un estereoisómero, una sal del mismo, o una fonda mórfica del mismo.
MX2019004492A 2016-10-18 2017-10-18 Metodos para tratar trastornos del higado o trastornos lipidicos con un agonista de thr-beta. MX2019004492A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662409833P 2016-10-18 2016-10-18
US201762516594P 2017-06-07 2017-06-07
PCT/US2017/057203 WO2018075650A1 (en) 2016-10-18 2017-10-18 Methods of treating liver disorders or lipid disorders with a thr-beta agonist

Publications (1)

Publication Number Publication Date
MX2019004492A true MX2019004492A (es) 2019-11-18

Family

ID=60480362

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019004492A MX2019004492A (es) 2016-10-18 2017-10-18 Metodos para tratar trastornos del higado o trastornos lipidicos con un agonista de thr-beta.

Country Status (12)

Country Link
US (3) US11090308B2 (es)
EP (2) EP3528817B1 (es)
JP (2) JP2019533019A (es)
KR (2) KR20230156159A (es)
CN (1) CN110167557A (es)
AU (1) AU2017346871B2 (es)
CA (1) CA3040888A1 (es)
DK (1) DK3528817T3 (es)
ES (1) ES2924257T3 (es)
IL (2) IL266054B2 (es)
MX (1) MX2019004492A (es)
WO (1) WO2018075650A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200023528A (ko) 2012-09-17 2020-03-04 마드리갈 파마슈티칼스, 인크. 갑상선 호르몬 유사체 및 이의 다형의 합성 방법
CA2968836A1 (en) 2016-06-13 2017-12-13 Gilead Sciences, Inc. Fxr (nr1h4) modulating compounds
EP3730487B1 (en) 2016-06-13 2022-04-27 Gilead Sciences, Inc. Azetidine derivatives as fxr (nr1h4) modulators
US11090308B2 (en) 2016-10-18 2021-08-17 Madrigal Pharmaceuticals, Inc. Methods of treating liver disorders or lipid disorders with a THR-beta agonist
PT3600309T (pt) 2017-03-28 2022-10-03 Gilead Sciences Inc Combinações terapêuticas para o tratamento de doenças hepáticas
CN111801324B (zh) * 2018-06-12 2021-10-22 四川海思科制药有限公司 甲状腺激素受体激动剂及其用途
CN110627773B (zh) * 2018-06-22 2021-03-19 海创药业股份有限公司 氘代mgl-3196化合物及其用途
TW202019914A (zh) * 2018-07-02 2020-06-01 美商瑪德瑞高製藥公司 ２-（３，５-二氯-４-（（５-異丙基-６-側氧基-１，６-二氫噠嗪-３-基）氧）苯基）-３，５-二側氧基-２，３，４，５-四氫-１，２，４-三嗪-６-腈之固體型式
MX2021002655A (es) * 2018-09-06 2021-05-27 Galmed Res And Development Ltd Terapia de combinacion para el tratamiento de enfermedad hepatica.
TWI840423B (zh) 2018-10-12 2024-05-01 美商拓臻股份有限公司 甲狀腺素受體β促效劑化合物
CN111320609A (zh) * 2018-12-13 2020-06-23 拓臻股份有限公司 一种THRβ受体激动剂化合物及其制备方法和用途
SI3911647T1 (sl) * 2019-01-15 2024-04-30 Gilead Sciences, Inc. Izoksazolna spojina kot agonist FXR in farmacevtski sestavki, ki jo obsegajo
JP2022519906A (ja) 2019-02-19 2022-03-25 ギリアード サイエンシーズ， インコーポレイテッド Ｆｘｒアゴニストの固体形態
JP7445996B2 (ja) * 2019-02-21 2024-03-08 ナンジン・ルイジェ・ファーマ・カンパニー・リミテッド 新規化合物及び甲状腺ホルモン受容体アゴニストとしてのそれらの使用
KR20220017917A (ko) 2019-05-08 2022-02-14 알리고스 테라퓨틱스 인코포레이티드 Thr-베타의 조절제 및 이의 사용 방법
WO2021041237A1 (en) * 2019-08-23 2021-03-04 Terns, Inc. Thyroid hormone receptor beta agonist compounds
JP2022548250A (ja) * 2019-09-12 2022-11-17 ターンズ・ファーマシューティカルズ・インコーポレイテッド 甲状腺ホルモン受容体ベータアゴニスト化合物
WO2021063367A1 (zh) * 2019-09-30 2021-04-08 苏州科睿思制药有限公司 一种Resmetirom晶型及其制备方法和用途
WO2021104288A1 (zh) * 2019-11-26 2021-06-03 昆药集团股份有限公司 1，2，4-三嗪-3，5-二酮类化合物及其制备方法和应用
CN111562321B (zh) * 2020-04-16 2022-10-28 广东省结核病控制中心 用于检测活动性肺结核的粪便代谢物及其检测系统
CN116171275A (zh) * 2020-09-10 2023-05-26 苏州科睿思制药有限公司 Resmetirom的晶型及其制备方法和用途
CA3195789A1 (en) 2020-10-19 2022-04-28 Teva Pharmaceuticals International Gmbh Solid state forms of resmetirom
AU2022213405A1 (en) * 2021-02-01 2023-08-03 Madrigal Pharmaceuticals, Inc. Therapeutic combinations of rosuvastatin and resmetirom for the treatment of liver disorders or lipid disorders
EP4373476A1 (en) * 2021-07-21 2024-05-29 Cyta Therapeutics, Inc. Particle delivery of thyroid hormone receptor agonists and antagonists

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5615272A (en) 1979-07-17 1981-02-14 Ishihara Sangyo Kaisha Ltd N-benzoyl-n'-phenylurea compound, its preparation, and insecticide containing the same
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
RU2344128C2 (ru) 2003-03-24 2009-01-20 Ф.Хоффманн-Ля Рош Аг Бензилпиридазиноны как ингибиторы обратной транскриптазы
ITRM20030363A1 (it) 2003-07-24 2005-01-25 Fernando Goglia Composizioni comprendenti la 3, 5diiodotironina e uso farmaceutico di esse.
US7498315B2 (en) 2004-06-01 2009-03-03 Pronai Therapeutics, Inc. Methods and compositions for the inhibition of gene expression
US7807647B2 (en) 2004-06-01 2010-10-05 Pronai Therapeutics, Inc. Methods and compositions for cancer therapy
PT1919878E (pt) 2005-07-21 2010-11-02 Hoffmann La Roche Derivados de piridazinona como agonistas do receptor da hormona da tiróide
DE602008002205D1 (de) 2007-06-06 2010-09-30 Torrent Pharmaceuticals Ltd Neuartige verbindungen
US8076334B2 (en) 2007-09-20 2011-12-13 Hoffmann-La Roche Inc. Prodrugs of thyroid hormone analogs
KR20200023528A (ko) * 2012-09-17 2020-03-04 마드리갈 파마슈티칼스, 인크. 갑상선 호르몬 유사체 및 이의 다형의 합성 방법
US8858502B2 (en) 2012-10-10 2014-10-14 Alcon Research, Ltd. Systems and methods for external pressure sensing
RU2016133471A (ru) * 2014-02-14 2018-03-19 Семпра Фармасьютикалс, Инк. Композиции и способы для лечения диабета и заболеваний печени
US11090308B2 (en) 2016-10-18 2021-08-17 Madrigal Pharmaceuticals, Inc. Methods of treating liver disorders or lipid disorders with a THR-beta agonist
TW202019914A (zh) 2018-07-02 2020-06-01 美商瑪德瑞高製藥公司 ２-（３，５-二氯-４-（（５-異丙基-６-側氧基-１，６-二氫噠嗪-３-基）氧）苯基）-３，５-二側氧基-２，３，４，５-四氫-１，２，４-三嗪-６-腈之固體型式

Also Published As

Publication number Publication date
JP2019533019A (ja) 2019-11-14
AU2017346871A1 (en) 2019-05-02
CN110167557A (zh) 2019-08-23
US20200230146A1 (en) 2020-07-23
KR20230156159A (ko) 2023-11-13
CA3040888A1 (en) 2018-04-26
US20210330675A1 (en) 2021-10-28
EP4112056A1 (en) 2023-01-04
JP2024001055A (ja) 2024-01-09
IL266054B1 (en) 2023-06-01
US11806353B2 (en) 2023-11-07
DK3528817T3 (da) 2022-08-08
AU2017346871B2 (en) 2023-08-03
KR20190109387A (ko) 2019-09-25
WO2018075650A1 (en) 2018-04-26
IL266054A (en) 2019-06-30
IL266054B2 (en) 2023-10-01
US20240156826A1 (en) 2024-05-16
EP3528817A1 (en) 2019-08-28
US11090308B2 (en) 2021-08-17
ES2924257T3 (es) 2022-10-05
IL302336A (en) 2023-06-01
EP3528817B1 (en) 2022-05-25

Similar Documents

Publication Publication Date Title
MX2019004492A (es) Metodos para tratar trastornos del higado o trastornos lipidicos con un agonista de thr-beta.
MX2024002223A (es) Dosificacion para el tratamiento con anticuerpos biespecificos anti-cd20/anti-cd3.
CL2018001556A1 (es) Receptores de antígenos quiméricos (car) de bcma. (solicitud divisional 201701515)
CR20170131A (es) Anticuerpos anti-her2 e inmunoconjugados
IL260442B (en) Combinations of anti-cd20 for cancer treatment
WO2015153514A8 (en) Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists
IL279700A (en) Solid structures of 2-(5,3-dichloro-4-((5-isopropyl-6-oxo-6,1-dihydropyridizin-3-yl)oxy)phenyl)-5,3-dioxo-5,4,3 ,2-tetrahydro-4,2,1-triazine-6-carbonitrile
ZA201807351B (en) Novel gpr119 agonist compounds
MX2018016057A (es) Composiciones y metodos para tratar enfermedades cardiovasculares.
MX2020003593A (es) Compuestos de benzotiazol y metodos para usar los mismos para tratar trastornos neurodegenerativos.
PL3426637T3 (pl) Związki i sposoby modulowania kinazy tyrozynowej brutona
BR112016026544A2 (pt) métodos para inibir a necroptose
MX2024006922A (es) Metodo de cromatografia para cuantificar un tensioactivo no ionico en una composicion que comprende el tensioactivo no ionico y un polipeptido.
SG11202100528YA (en) Proteogenomic-based method for identifying tumor-specific antigens
SG11202102162RA (en) Anti-trem-2 agonist antibodies
IL281052A (en) Treatment of liver disorders
EP3525499A4 (en) SESSION MANAGEMENT METHOD
IL286489A (en) Wave scattering-based microscopy
IL283654A (en) Decarboxylase inhibitors for the treatment of Parkinson's disease
EP3537155A4 (en) METHOD FOR DETERMINING THE RISK OF MORBUS ALZHEIMER
MX2015009155A (es) Uso de agonistas del receptor nicotinico de acetilcolina alfa 7.
EP3902790C0 (de) Verbessertes verfahren zur herstellung von 4,6-dihydroxypyrimidin
PL3802665T3 (pl) Alkoksylowane poliamidoaminy jako środki dyspergujące
MA50459A (fr) Ioniseur équipé d'un accélérateur de flux ionique notamment pour la protection contre les moustiques
MA51888A (fr) Collier de serrage à insérer pour tuyaux pourvu de plaque de fond